用于激素替代疗法的雌二醇黏膜黏附口腔膜:开发与体内性能预测

Mucoadhesive Buccal Film of Estradiol for Hormonal Replacement Therapy: Development and In-Vivo Performance Prediction.

作者信息

Abdella Sadikalmahdi, Afinjuomo Franklin, Song Yunmei, Upton Richard, Garg Sanjay

机构信息

Pharmaceutical Innovation and Development (PIDG) Group, Clinical and Health Sciences, University of South Australia, Adelaide, SA 5000, Australia.

School of Pharmacy, College of Health Sciences, Addis Ababa University, Zambia St., Addis Ababa 1000, Ethiopia.

出版信息

Pharmaceutics. 2022 Feb 28;14(3):542. doi: 10.3390/pharmaceutics14030542.

Abstract

The age-related loss of circulating estrogen that occurs during the menopausal transition manifests itself through a variety of symptoms including vasomotor (hot flushes and night sweats), genito-urinary syndrome (vaginal dryness and urinary symptoms), sexual dysfunction, mood, and sleep disturbance that often last longer than a decade. Furthermore, reductions in estrogen level increase the risks of chronic complications such as osteoporosis, cardiovascular disease, and cognitive decline among others, thereby affecting the quality of life of women. Although oral estrogens are the most widely used therapy for menopausal symptoms, they suffer from poor bioavailability, and there are concerns over their safety, creating a significant concern to consumers. Mucoadhesive buccal films are an innovative dosage form that offers several advantages including avoidance of the first-pass metabolism, fast onset of action, and importantly, improved patient acceptance. In the current work, we developed mucoadhesive estradiol film for hormonal replacement therapy using film-forming polymers. Two approaches, namely, co-solvency and nano-emulsion were evaluated to increase solubility and hence incorporate estradiol, a poorly water-soluble drug, into a formulation made from the hydrophilic polymer/s. The films were characterised for their mechanical and physicochemical properties. In-vitro release study showed that about 80% of the drug was released within 6 min from films prepared by the nano-emulsion approach, whereas it took about 10.5 min to get similar drug release from films prepared by the co-solvency approach. The ex-vivo permeation result indicates that about 15% of the drug permeated across the porcine buccal mucosa in the first 10 h from films prepared by the nano-emulsion approach, while permeation across porcine buccal mucosa was only observed at around 24 h from films prepared by the co-solvency method. The nano-emulsion films were evaluated for in vivo performance using a convolution technique using R software. The predicted Cmax and Tmax were found to be 740.74 ng mL and 7 min, respectively, which were higher than previously reported in vivo concentration from oral tablets. The results demonstrated that mucoadhesive film of estradiol based on the nano-emulsion approach could be a promising platform for the delivery of estradiol through the buccal mucosa for the treatment of menopausal symptoms.

摘要

绝经过渡期间发生的与年龄相关的循环雌激素丧失通过多种症状表现出来,包括血管舒缩症状(潮热和盗汗)、泌尿生殖综合征(阴道干燥和泌尿症状)、性功能障碍、情绪和睡眠障碍,这些症状通常会持续十多年。此外,雌激素水平降低会增加慢性并发症的风险,如骨质疏松症、心血管疾病和认知能力下降等,从而影响女性的生活质量。尽管口服雌激素是治疗绝经症状最广泛使用的疗法,但它们的生物利用度差,并且人们对其安全性存在担忧,这引起了消费者的重大关注。粘膜粘附性口腔膜是一种创新剂型,具有多种优点,包括避免首过代谢、起效快,重要的是,提高了患者的接受度。在当前的工作中,我们使用成膜聚合物开发了用于激素替代疗法的粘膜粘附性雌二醇膜。评估了两种方法,即共溶剂法和纳米乳液法,以提高溶解度,从而将水溶性差的药物雌二醇纳入由亲水性聚合物制成的制剂中。对这些膜的机械和物理化学性质进行了表征。体外释放研究表明,通过纳米乳液法制备的膜在6分钟内释放了约80%的药物,而通过共溶剂法制备的膜达到类似的药物释放则需要约10.5分钟。体外渗透结果表明,通过纳米乳液法制备的膜在最初10小时内约15%的药物渗透过猪口腔粘膜,而通过共溶剂法制备的膜在约24小时才观察到药物渗透过猪口腔粘膜。使用R软件的卷积技术对纳米乳液膜的体内性能进行了评估。预测的Cmax和Tmax分别为740.74 ng/mL和7分钟,高于先前报道的口服片剂的体内浓度。结果表明,基于纳米乳液法的雌二醇粘膜粘附膜可能是通过口腔粘膜递送雌二醇以治疗绝经症状的有前途的平台。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e733/8955147/f68c1fb69b29/pharmaceutics-14-00542-g001.jpg

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索